Royal DSM NV (DSM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Royal DSM NV (DSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9888
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Royal DSM NV (DSM) is a science-based company with focus on materials, health and nutrition. It produces vitamins, carotenoids, nutritional lipids and other ingredients; specialty plastics; and fiber and resins solutions. DSM develops materials for medical devices and clean energy from crop residues and bio-chemicals. The company serves customers in animal nutrition and health, packaging and graphic arts, building and construction, pharma solutions, electrical and electronics, automotive, medical, personal care, energy, food, furniture, life protection, beverages and dietary supplements, marine, paint and coatings, manufacturing and equipment, sports, leisure and consumer goods, and textiles and clothing sectors. The company has operations across Eastern Europe, Latin America, North America, Asia, and other regions. DSM is headquartered in Heerlen, the Netherlands.

Royal DSM NV (DSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Royal DSM NV, Medical Devices Deals, 2012 to YTD 2018 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Royal DSM NV, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Private Equity 16
Bain Capital Private Equity Acquires DSM Sinochem Pharma from Royal DSM and Sinochem Group 16
Partnerships 18
Aerie Pharma Enters into R&D Agreement with Royal DSM 18
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 19
Royal DSM Forms Joint Venture With JLL Partners 20
Licensing Agreements 22
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 22
Equity Offering 23
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 23
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Debt Offering 28
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Acquisition 31
Royal DSM Acquires Amyris Brasil 31
Royal DSM Acquires Biocare Copenhagen 32
i-Health to Acquire UP4 Probiotics from UAS Labs 33
Royal DSM Acquires Aland Nutraceutical 34
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 35
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 37
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 39
Royal DSM NV – Key Competitors 41
Royal DSM NV – Key Employees 42
Royal DSM NV – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Joint Venture 46
Recent Developments 48
Strategy And Business Planning 48
Apr 03, 2017: Royal DSM Opens New Biotechnology Center in Delft, the Netherlands 48
Financial Announcements 49
Aug 01, 2018: DSM announces H1 2018 results 49
May 08, 2018: DSM Reports Q1 2018 Results 50
Feb 15, 2018: DSM Reports 2017 Results 51
Nov 02, 2017: DSM Reports Results First Nine Months 2017 58
May 02, 2017: DSM Q1 2017 Results 59
Feb 15, 2017: DSM reports 2016 results 60
Feb 14, 2017: DSM new presentation of accounts as from Q4 2016 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Royal DSM NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Royal DSM NV, Deals By Therapy Area, 2012 to YTD 2018 9
Royal DSM NV, Medical Devices Deals, 2012 to YTD 2018 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Bain Capital Private Equity Acquires DSM Sinochem Pharma from Royal DSM and Sinochem Group 16
Aerie Pharma Enters into R&D Agreement with Royal DSM 18
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 19
Royal DSM Forms Joint Venture With JLL Partners 20
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 22
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 23
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Royal DSM Acquires Amyris Brasil 31
Royal DSM Acquires Biocare Copenhagen 32
i-Health to Acquire UP4 Probiotics from UAS Labs 33
Royal DSM Acquires Aland Nutraceutical 34
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 35
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 37
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 39
Royal DSM NV, Key Competitors 41
Royal DSM NV, Key Employees 42
Royal DSM NV, Other Locations 43
Royal DSM NV, Subsidiaries 43
Royal DSM NV, Joint Venture 46

List of Figures
Royal DSM NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Royal DSM NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Royal DSM NV, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Royal DSM NV (DSM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Brookfield Office Properties Inc:企業のM&A・事業提携・投資動向
    Brookfield Office Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brookfield Office Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Exosome Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • PledPharma AB (PLED):製薬・医療:M&Aディール及び事業提携情報
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Cabot Oil & Gas Corp (COG):石油・ガス:M&Aディール及び事業提携情報
    Summary Cabot Oil & Gas Corp (Cabot) is an independent oil and gas company, which develops, and explores for oil and gas properties primarily in the continental US. It focuses on developing natural gas resources in the Marcellus shale in northeast Pennsylvania and oil development in the Eagle Ford s …
  • Dynatronics Corp (DYNT):医療機器:M&Aディール及び事業提携情報
    Summary Dynatronics Corp (Dynatronics) is a medical device company that offers rehab technology and equipment solutions. The company offers modalities, hot and cold therapy, clinical accessories, body positioning, sports medicine, orthopedics, hand therapy, strength equipment, treatment tables and r …
  • Toro Energy Limited (TOE):企業の戦略的SWOT分析
    Toro Energy Limited (TOE) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Equifax Inc.:企業の戦略・SWOT・財務情報
    Equifax Inc. - Strategy, SWOT and Corporate Finance Report Summary Equifax Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • InVivoScribe Technologies Inc:企業の製品パイプライン分析
    Summary InVivoScribe Technologies Inc (InVivoScribe) is a provider of hematology-oncology testing products and services. The company offer full range of hematology-oncology testing products and services. It’s products include lymphotrack and lymphotrack DX assay kits, and custom assay and reagent de …
  • Luxair S.A.:企業の戦略・SWOT・財務情報
    Luxair S.A. - Strategy, SWOT and Corporate Finance Report Summary Luxair S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Mitek Systems Inc (MITK):企業の財務・戦略的SWOT分析
    Summary Mitek Systems Inc (Mitek) is a technology company that develops and markets payment and fraud prevention software products. The company offers products such as Mobile Verify, Mobile Docs, Mobile Fill, Mobile Deposit and Multi Check Capture. Its Mobile Verify is a Mitek's ID verification solu …
  • Polimex-Mostostal SA (PXM):企業の財務・戦略的SWOT分析
    Polimex-Mostostal SA (PXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • William Hill plc (WMH):企業の財務・戦略的SWOT分析
    William Hill plc (WMH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Holly Energy Partners LP:企業のM&A・事業提携・投資動向
    Holly Energy Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Holly Energy Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • TRACON Pharmaceuticals Inc (TCON):企業の財務・戦略的SWOT分析
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its le …
  • Bina Puri Holdings Bhd:企業の戦略・SWOT・財務情報
    Bina Puri Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Bina Puri Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Broadridge Financial Solutions, Inc. (BR):企業の財務・戦略的SWOT分析
    Broadridge Financial Solutions, Inc. (BR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • MISC Berhad (MISC):石油・ガス:M&Aディール及び事業提携情報
    Summary MISC Bhd (MISC), a subsidiary of Petroliam Nasional Berhad (Petronas), is an international energy shipping and maritime conglomerate. The company is a fully integrated maritime, offshore floating solution, heavy engineering and logistics service provider. Its principal business activities in …
  • Services Group of America:企業の戦略・SWOT・財務情報
    Services Group of America - Strategy, SWOT and Corporate Finance Report Summary Services Group of America - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • PricewaterhouseCoopers LLP:企業の戦略的SWOT分析
    PricewaterhouseCoopers LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Vaccinex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Vaccinex Inc (Vaccinex) is a clinical-stage biotechnology company that focuses on the discovery and development of targeted biotherapeutics to treat neurodegenerative diseases, cancer and autoimmune disorders. The company’s lead platform technologies include SEMA4D, antibody platform and Act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆